Skip to main content
Signal8

InMed Pharmaceuticals Inc. (INM) Form 8-K — Nov 10, 2026

$INMForm 8-KItems 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 9.01Filed Nov 10, 2026, 4:45 PM ET0001193125-26-455640Original filing

InMed Pharmaceuticals completed its reverse merger with privately held Mentari Therapeutics on November 6, 2026, and the combined company — renamed Mentari Therapeutics, Inc. — began trading on Nasdaq under the new ticker MTRI on November 9, 2026. The deal was transformative and heavily dilutive to legacy InMed holders: after a 1-for-10 reverse split, a redomestication from Canada to Nevada, and a ~$490.0 million pre-closing PIPE, former InMed shareholders retain only about 1% of the company on a fully diluted basis, with Mentari holders owning ~99%.

Key figures

Gross Proceeds
490000000
Shares Offered
215042178
New ticker
MTRI
Exchange ratio
0.20065 shares of Company Common Stock per Mentari share
Prefunded warrants
7317328
Reverse split ratio
1:10
Mentari valuation in financing
125000000
Shares outstanding post merger
52813914
Cvr business development budget
100000
Fully diluted shares post merger
58295136
Inmed holders ownership post merger
~1.0%
Mentari holders ownership post merger
~99.0%

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.